May 11, 2020
Save Nil's Life: Crowdfunding Campaign Created in Fight Against Spinal Muscular Atrophy (SMA) Type 2
Nov 11, 2019
Risdiplam (RG7916) Pivotal SUNFISH Study Demonstrates Statistically Significant Improvement for Patients with Type 2/3 Spinal Muscular Atrophy
May 24, 2019
MDA Celebrates FDA Approval of Zolgensma for Treatment of Spinal Muscular Atrophy in Pediatric Patients
May 24, 2019
AveXis Announces Innovative Zolgensma® Gene Therapy Access Programs for US Payers and Families
May 24, 2019
AveXis receives FDA approval for Zolgensma®, the first and only gene therapy for pediatric patients with spinal muscular atrophy (SMA)
May 05, 2019
AveXis presented robust data at AAN demonstrating efficacy of Zolgensma® in broad spectrum of spinal muscular atrophy (SMA) patients
Oct 03, 2018
Risdiplam Demonstrates Preliminary Evidence of Clinical Benefit in Type 1, 2, & 3 Spinal Muscular Atrophy Patients
Jun 16, 2018
Updated Preliminary Data from SMA FIREFISH Program in Type 1 Babies Presented at the CureSMA Conference
Apr 27, 2018
Invitae Announces New Program to Offer Genetic Testing to Aid Diagnosis of Spinal Muscular Atrophy (SMA)
Apr 18, 2018
Preliminary Study Suggests Drug May Help Babies with Spinal Muscular Atrophy
Jan 27, 2018
Preliminary Data from FIREFISH trial in Type 1 SMA Infants Presented at the International Scientific Congress on Spinal Muscular Atrophy
Nov 16, 2017
Canon BioMedical launches assays for spinal muscular atrophy research
Jun 22, 2017
Spotlight Innovation to Present Poster at the Cure SMA 2017 Annual SMA Conference